Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:LVTX NASDAQ:VIVS NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.49+1.4%$5.04$1.00▼$7.00$39.83M0.4196,854 shs1,664 shsLVTXLAVA Therapeutics$1.57+0.6%$1.51$0.85▼$2.09$41.30M0.5223,297 shs216,056 shsVIVSVivoSim Labs$3.86+3.8%$2.37$1.41▼$21.96$10.04M1.11418,013 shs59,825 shsXLOXilio Therapeutics$0.75-1.4%$0.70$0.62▼$1.70$39.08M-0.141.93 million shs133,811 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-1.12%-4.53%-11.75%+0.11%+260.16%LVTXLAVA Therapeutics+5.05%+1.30%+1.96%+17.65%-4.29%VIVSVivoSim Labs-10.36%-22.18%+76.30%+142.35%+371,999,900.00%XLOXilio Therapeutics-1.92%+1.77%+8.80%+15.84%-1.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.49+1.4%$5.04$1.00▼$7.00$39.83M0.4196,854 shs1,664 shsLVTXLAVA Therapeutics$1.57+0.6%$1.51$0.85▼$2.09$41.30M0.5223,297 shs216,056 shsVIVSVivoSim Labs$3.86+3.8%$2.37$1.41▼$21.96$10.04M1.11418,013 shs59,825 shsXLOXilio Therapeutics$0.75-1.4%$0.70$0.62▼$1.70$39.08M-0.141.93 million shs133,811 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-1.12%-4.53%-11.75%+0.11%+260.16%LVTXLAVA Therapeutics+5.05%+1.30%+1.96%+17.65%-4.29%VIVSVivoSim Labs-10.36%-22.18%+76.30%+142.35%+371,999,900.00%XLOXilio Therapeutics-1.92%+1.77%+8.80%+15.84%-1.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00167.26% UpsideLVTXLAVA Therapeutics 2.00Hold$2.6971.02% UpsideVIVSVivoSim Labs 0.00N/AN/AN/AXLOXilio Therapeutics 3.33Buy$3.00297.88% UpsideCurrent Analyst Ratings BreakdownLatest VIVS, LVTX, ATHE, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025XLOXilio TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025XLOXilio TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$2.008/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.50(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ALVTXLAVA Therapeutics$4.99M8.28N/AN/A$1.06 per share1.48VIVSVivoSim Labs$140K71.69N/AN/A$5.54 per share0.70XLOXilio Therapeutics$6.34M6.16N/AN/A$0.40 per share1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/A0.00∞N/AN/AN/AN/AN/ALVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%12/9/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,396.48%-32.95%-21.31%N/AXLOXilio Therapeutics-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)Latest VIVS, LVTX, ATHE, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025XLOXilio Therapeutics-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/A8/12/2025Q1 2026VIVSVivoSim LabsN/A-$1.14N/A-$1.14N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.9812.98LVTXLAVA TherapeuticsN/A10.7810.78VIVSVivoSim LabsN/A4.524.52XLOXilio TherapeuticsN/A2.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%LVTXLAVA TherapeuticsN/AVIVSVivoSim Labs8.23%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%LVTXLAVA Therapeutics9.50%VIVSVivoSim Labs3.72%XLOXilio Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableVIVSVivoSim Labs202.60 million2.50 millionN/AXLOXilio Therapeutics7051.83 million48.56 millionNot OptionableVIVS, LVTX, ATHE, and XLO HeadlinesRecent News About These CompaniesXilio Therapeutics sees cash runway into 1Q27September 9, 2025 | msn.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under ...September 9, 2025 | finance.yahoo.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadSeptember 9, 2025 | globenewswire.comXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29, 2025 | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28, 2025 | tipranks.comXLO | Xilio Therapeutics Inc. Annual Cash Flow Statement | MarketWatchAugust 16, 2025 | marketwatch.comXilio Therapeutics reports Q2 EPS (16c) vs (24c) last yearAugust 15, 2025 | msn.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 15, 2025 | taiwannews.com.twTXilio Revenue Jumps 246 Percent in Q2August 15, 2025 | aol.comAXilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesAugust 14, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform RecommendationAugust 7, 2025 | msn.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics expands board, elects new directorJune 12, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comQXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Not Just NVDA: 3 Semiconductor Stocks Struggling This QuarterBy Dan Schmidt | September 12, 2025VIVS, LVTX, ATHE, and XLO Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.49 +0.06 (+1.35%) As of 03:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.LAVA Therapeutics NASDAQ:LVTX$1.57 +0.01 (+0.64%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.VivoSim Labs NASDAQ:VIVS$3.86 +0.14 (+3.76%) As of 03:04 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.Xilio Therapeutics NASDAQ:XLO$0.75 -0.01 (-1.44%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
